Philips accelerates stroke diagnosis and treatment with expanded integrated solutions and strategic partnership
07 July 2021 - 06:05PM
July 7, 2021
- Expanded capabilities of Philips Image Guided Therapy System –
Azurion – and new collaboration with NICO.LAB add to the latest
advances in Philips’ commitment to reduce time to stroke treatment,
a key factor in improving outcomes
- Partnership enhances Philips’ deep portfolio of solutions
across the stroke care pathway with advanced artificial
intelligence and cloud capabilities, strengthening care
collaboration and optimizing decision making at each step
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced a strategic partnership agreement with NICO.LAB, a
MedTech stroke care company. Together with the recently expanded
stroke capabilities of Philips Image Guided Therapy System –
Azurion – this new partnership significantly advances Philips’
commitment to improving outcomes for people who suffer a stroke.
Philips is connecting information, technologies and people across
the stroke care pathway, enabling care teams to work quickly and
act decisively - a key factor in providing the best patient
treatment.
Stroke remains the leading cause of disability
Globally, one in four adults over the age of 25 will suffer a
stroke in their lifetime [1]. Stroke is the leading cause of
disability and the second leading cause of death worldwide [2].
According to the U.S. National Stroke Association, 40% of stroke
victims experience moderate to severe impairments that require
special needs for the rest of their lives, with another 25%
continuing to suffer minor impairments [3].
The key to reducing the risk of death or disability is to get
stroke patients treated as quickly as possible. Physicians in an
emergency stroke setting are fighting the clock and are under
intense pressure to make optimal treatment decisions. Despite
the imperative for speed, care teams currently lose valuable time
due to gaps in communication, information, and access to stroke
expertise.
“The biggest gain for faster treatment for stroke patients is in
the workflow,” said Professor Dr. Wim van Zwam, Interventional
Radiologist at Maastricht University Medical Center. “Reducing the
throughput time of patients requires faster exchange of critical
patient information, such as high-quality medical images, between
hospitals and departments, in order to decide on the best patient
treatment.”
Solutions across the stroke care pathwayPhilips
has a deep portfolio of stroke care solutions and a strong
commitment to further innovation in this field. Its partnership
with NICO.LAB brings a cloud-based, end-to-end artificial
intelligence (AI) based stroke triage and management solution -
StrokeViewer - that aims to improve patient outcome by optimizing
the stroke workflow. It analyzes CT scan data with AI, and
automatically detects large vessel occlusion (LVO) and its
location. It then shares this analysis with physicians at both
primary stroke centers (general radiologists and neurologist) and
intervention centers (stroke neurologists, interventional
neurologists, and radiologists) where the patient is eventually
treated.
Recent Philips innovations that optimize the imaging
capabilities of its Image Guided Therapy Angiography Suite with new
3D visualization and measurement tool – SmartCT – aim to get
patients into treatment quickly.
Philips is also pioneering a new approach to speed up stroke
treatment for early time-window stroke patients (less than six
hours after stroke onset) by bypassing diagnostic CT or MR scans at
certain types of stroke center. Earlier today, Philips announced
the first patient being enrolled in the WE-TRUST study - a global
multi-center randomized clinical trial to assess the impact of a
Direct to Angio Suite workflow focusing on improving care for
stroke patients. This approach can allow for quick patient routing,
and with the new SmartCT imaging capabilities in Philips’ Azurion
Angio Suite, further diagnosis can be done to confirm eligibility
for treatment.
“By expanding our offerings in stroke care we are able to
provide an integrated portfolio of intelligent solutions across the
full stroke care pathway, giving clinicians the right information
during every critical step,” said Bert van Meurs, Chief Business
Leader for Image Guided Therapy at Philips. “With our integrated
portfolio, and by using validated AI and cloud technologies, we can
facilitate collaborative care to optimize the stroke care pathway
from diagnosis to treatment.”
Philips’ stroke portfolio includes solutions for stroke
monitoring and communication in ambulances, tele-stroke patient
assessment, diagnostic imaging and analysis, image-guided therapy,
neurological monitoring and assessment, and more.
[1] World Stroke Organization[2] Global Burden of Stroke,
PubMed.[3] U.S. National Stroke Association
For further information, please contact:
Joost MalthaPhilips Global Press OfficeTel: +31 610 558
116Email: joost.maltha@philips.comTwitter: JoostMaltha
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.comTwitter: FC_Feer
About Royal Philips Royal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being, and enabling better
outcomes across the health continuum – from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2020
sales of EUR 17.3 billion and employs approximately 77,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter
About NICO.LABAt NICO.LAB, we believe connecting
human and artificial intelligence will revolutionize emergency
care. Founded in 2015, NICO.LAB is a MedTech company that stems
from leading clinical research. We develop
end-to-end solutions to further empower physicians in
emergency care. Powered by unique datasets, our artificial
intelligence product StrokeViewer® significantly enhances stroke
patient outcomes by reducing time to treatment. With CE, TGA and
FDA clearance and following a recent successful investment round,
we are destined to enhance patient outcomes all over the world.
Learn more on www.nico-lab.com Follow us on
www.linkedin.com/company/nico-lab
- Philips Image Guided Therapy System Azurion NeuroSuite
- Nico.lab StrokeViewer
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2023 to Mar 2024